McCubrey James A, Davis Nicole M, Abrams Stephen L, Montalto Giuseppe, Cervello Melchiorre, Libra Massimo, Nicoletti Ferdinando, D'Assoro Antonino B, Cocco Lucio, Martelli Alberto M, Steelman Linda S
Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Brody Building 5N98C, Greenville, NC 27858, USA.
Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Brody Building 5N98C, Greenville, NC 27858, USA.
Adv Biol Regul. 2014 Sep;56:81-107. doi: 10.1016/j.jbior.2014.05.003. Epub 2014 May 22.
Over the past 10 years there have been significant advances in our understanding of breast cancer and the important roles that breast cancer initiating cells (CICs) play in the development and resistance of breast cancer. Breast CICs endowed with self-renewing and tumor-initiating capacities are believed to be responsible for the relapses which often occur after various breast cancer therapies. In this review, we will summarize some of the key developments in breast CICs which will include discussion of some of the key genes implicated: estrogen receptor (ER), HER2, BRCA1, TP53, PIK3CA, RB, P16INK1 and various miRs as well some drugs which are showing promise in targeting CICs. In addition, the concept of combined therapies will be discussed. Basic and clinical research is resulting in novel approaches to improve breast cancer therapy by targeting the breast CICs.
在过去十年中，我们对乳腺癌以及乳腺癌起始细胞（CICs）在乳腺癌发展和耐药中所起的重要作用有了重大进展。具有自我更新和肿瘤起始能力的乳腺CICs被认为是导致各种乳腺癌治疗后经常复发的原因。在这篇综述中，我们将总结乳腺CICs的一些关键进展，其中包括对一些关键基因的讨论：雌激素受体（ER）、HER2、BRCA1、TP53、PIK3CA、RB、P16INK1和各种miR，以及一些在靶向CICs方面显示出前景的药物。此外，还将讨论联合治疗的概念。基础和临床研究正在产生通过靶向乳腺CICs来改善乳腺癌治疗的新方法。
